Skip to main content

Table 3 Hemodynamic parameters

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

Parameters

ZL

(n = 7–10)

ZDF

(n = 7)

ZDF + Zn(ASA)2

(n = 6)

ZL + Zn(ASA)2

(n = 9)

Basic hemodynamic data

 Heart rate (beats/min)

366 ± 12

346 ± 14

355 ± 12

373 ± 13

 SBP (mmHg)

138 ± 5

151 ± 6

153 ± 6

141 ± 7

 DBP (mmHg)

106 ± 3

108 ± 7

110 ± 5

107 ± 6

 MAP (mmHg)

112 ± 4

122 ± 7

124 ± 5

118 ± 6

 CO (ml/min)

31.0 ± 2.8

35.6 ± 5.3

35.6 ± 2.3

30.2 ± 4.1

Systolic function

 Stroke volume (µl)

85 ± 7

93 ± 13

100 ± 5

81 ± 11

 Stroke work (mmHg*ml)

8.56 ± 0.88

10.71 ± 1.28

11.25 ± 0.78

7.86 ± 1.09

 LVESP (mmHg)

131 ± 5

131 ± 6

128 ± 7

133 ± 7

 Ees (mmHg/µl)

1.13 ± 0.13

0.75 ± 0.11

0.85 ± 0.06

1.18 ± 0.24

Diastolic function

 Tau (Weiss) (ms)

9.8 ± 0.3

10.3 ± 0.7

10.2 ± 0.3

9.9 ± 0.4

  1. In vivo cardiac catheterization findings of ZDF (Zucker diabetic fatty) and Zucker lean (nondiabetic) rats after 24 days of treatment with either vehicle or Zn(ASA)2. Values are mean ± SEM, * P < 0.05 vs. ZL, $ P < 0.05 vs. ZL + Zn(ASA)2
  2. Zn(ASA) 2 indicates a zinc complex of acetylsalicylic acid, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean blood pressure, CO cardiac output, LVESP left ventricular end systolic pressure, E es the slope Ees of the left ventricular end-systolic pressure–volume relationship, Tau time constant of left ventricular decay, n number of animals analysed